Avatrombopag 20 MG ( DrugBank: Avatrombopag )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 60 | Aplastic anemia | 2 |
60. Aplastic anemia
Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05571332 (ClinicalTrials.gov) | June 28, 2022 | 28/8/2022 | Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function | Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function | Aplastic Anemia | Drug: Avatrombopag 20 MG Oral Tablet | Institute of Hematology & Blood Diseases Hospital | NULL | Recruiting | 18 Years | 70 Years | All | 39 | N/A | China |
| 2 | NCT04728789 (ClinicalTrials.gov) | February 1, 2021 | 1/12/2020 | Avatrombopag Usage in NSAA | Efficacy and Safety of Avatrombopag in Non-severe Aplastic Anemia - a Multicenter Prospective Single Arm Study | Aplastic Anemia;Drug Effect | Drug: Avatrombopag 20 MG | Peking Union Medical College Hospital | NULL | Not yet recruiting | 18 Years | 75 Years | All | 40 | Phase 2/Phase 3 | China |